A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.

A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2013 May; 139(1):145-53.

View in: PubMed

subject areas

Adult
Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Female
Humans
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor I
Insulin-Like Growth Factor II
Maximum Tolerated Dose
Middle Aged
Neoplasm Metastasis
Receptor, IGF Type 1
Sirolimus

authors with profiles

Rita Nanda
Gini Fleming
Olufunmilayo Olopade